GlassScriptPhysician profile
Norman D Baker
NPI 1790761476
$11,214.96
in general payments reported to CMS, 2019-2025
20 companies · $9,288 in 2025
The $9,288 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $81.55 · 2021: $288 · 2022: $243 · 2023: $252 · 2024: $298 · 2025: $9,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,822 · Consulting Fee: $2,940 · Food and Beverage: $2,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,822.25 |
| Consulting Fee | $2,940.00 |
| Food and Beverage | $2,075.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $4,786.99 | 2023-2025 | Preserflo Microshunt, Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| W. L. Gore & Associates, INC. | $4,109.67 | 2025 | Product In Development |
| Aerie Pharmaceuticals, INC. | $426.98 | 2019-2021 | |
| Abbvie INC. | $290.75 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Allergan, INC. | $239.80 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $194.00 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $182.87 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $148.98 | 2019-2022 | |
| Dompe US, INC. | $120.10 | 2024-2025 | Oxervate |
| Alcon Vision LLC | $113.10 | 2022-2025 | Rocklatan, Clareon |
| Kala Pharmaceuticals, INC. | $98.79 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $91.84 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $83.25 | 2022 | |
| New World Medical,INC. | $81.74 | 2021-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Biotissue Holdings INC. | $80.44 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60.99 | 2024-2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $59.85 | 2024-2025 | Purified Cortrophin Gel |
| Johnson & Johnson Surgical Vision, INC. | $19.30 | 2021 | |
| Mallinckrodt Enterprises LLC | $13.52 | 2019 | |
| Ocular Therapeutix, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.